<DOC>
	<DOCNO>NCT01571388</DOCNO>
	<brief_summary>The study determine difference dacomitinib absorb eliminate healthy subject subject mild moderately impaired hepatic function .</brief_summary>
	<brief_title>A Study To Compare Pharmacokinetics Of Dacomitinib ( PF-00299804 ) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject nonchildbearing potential age 18 year age &lt; 75 year age . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Liver function test , albumin prothrombin time must within normal range . Body Mass Index ( BMI ) 18 35 kg/m2 ; An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Subjects normal hepatic function group ( Group 1 ) : No know suspect hepatic impairment . For subject hepatic impairment group ( Groups 2 3 ) : Should satisfy criterion Class A B modify ChildPugh classification A diagnosis hepatic dysfunction due hepatocellular disease ( secondary acute ongoing hepatocellular process ) document medical history , physical examination , liver biopsy , hepatic ultrasound , CT scan , MRI . Stable hepatic impairment , define clinically significant change disease status within last 30 day , document subject 's recent medical history Must stable dose medication and/or treatment regimen . Any condition possibly affect drug absorption ( eg , gastrectomy , chronic diarrhea , rapid transit ) . A positive urine drug screen . Females childbearing potential , include tubal ligation . [ To consider enrollment , woman least 45 year age postmenopausal ( define amenorrheic least 2 year ) must confirmatory FSH test result screen ] . In addition , subject hepatic impairment group ( Groups 2 3 ) presenting follow included trial : Hepatic carcinoma hepatorenal syndrome life expectancy &lt; 1 year . Undergone portacaval shunt surgery . History gastrointestinal hemorrhage due esophageal varix peptic ulcer less one month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>dacomitinib</keyword>
	<keyword>PF-00299804</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>